Van Cutsem E - Search Results

1

Improving outcomes in colorectal cancer: where do we go from here?

Van Cutsem E, Borràs JM, Castells A, Ciardiello F, Ducreux M, Haq A, Schmoll HJ, Tabernero J. Van Cutsem E, et al. Eur J Cancer. 2013 Jul;49(11):2476-85. doi: 10.1016/j.ejca.2013.03.026. Epub 2013 Apr 30. Eur J Cancer. 2013. PMID: 23642327 Free article. Review.

2

Pancreatic cancer: a plea for more trials.

Van Cutsem E, Fevery J. Van Cutsem E, et al. Eur J Cancer. 1995 Jun;31A(6):867-9. doi: 10.1016/0959-8049(95)00002-x. Eur J Cancer. 1995. PMID: 7544144 No abstract available.

3

Screening for colorectal cancer.

Van Cutsem E, Tejpar S, Rutgeerts P, Janssens J. Van Cutsem E, et al. Acta Gastroenterol Belg. 1995 Sep-Dec;58(5-6):397-404. Acta Gastroenterol Belg. 1995. PMID: 8775996

4

A glimpse of the future. new directions in the treatment of colorectal cancer.

Van Cutsem E. Van Cutsem E. Eur J Cancer. 1996;32A Suppl 5:S23-7. doi: 10.1016/s0959-8049(96)00320-6. Eur J Cancer. 1996. PMID: 8958039 Review.

5

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P, Jacques C. Rougier P, et al. Among authors: van cutsem e. Lancet. 1998 Oct 31;352(9138):1407-12. doi: 10.1016/S0140-6736(98)03085-2. Lancet. 1998. PMID: 9807986 Clinical Trial.

6

A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer.

Van Cutsem E, Pozzo C, Starkhammar H, Dirix L, Terzoli E, Cognetti F, Humblet Y, Garufi C, Filez L, Gruia G, Cote C, Barone C. Van Cutsem E, et al. Ann Oncol. 1998 Nov;9(11):1199-204. doi: 10.1023/a:1008478405634. Ann Oncol. 1998. PMID: 9862050 Free article. Clinical Trial.

7

Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU).

Van Cutsem E, Cunningham D, Ten Bokkel Huinink WW, Punt CJ, Alexopoulos CG, Dirix L, Symann M, Blijham GH, Cholet P, Fillet G, Van Groeningen C, Vannetzel JM, Levi F, Panagos G, Unger C, Wils J, Cote C, Blanc C, Hérait P, Bleiberg H. Van Cutsem E, et al. Among authors: van groeningen c. Eur J Cancer. 1999 Jan;35(1):54-9. doi: 10.1016/s0959-8049(98)00353-0. Eur J Cancer. 1999. PMID: 10211088 Free article. Clinical Trial.

8

Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group.

Van Cutsem E, Blijham GH. Van Cutsem E, et al. Semin Oncol. 1999 Feb;26(1 Suppl 5):13-20. Semin Oncol. 1999. PMID: 10213010 Clinical Trial.

9

The medical treatment of colorectal cancer: actual status and new developments.

Van Cutsem E, Peeters M, Verslype C, Filez L, Haustermans K, Janssens J. Van Cutsem E, et al. Hepatogastroenterology. 1999 Mar-Apr;46(26):709-16. Hepatogastroenterology. 1999. PMID: 10370599 Review.

10

Raltitrexed (Tomudex) in combination treatment for colorectal cancer: new perspectives.

Van Cutsem E. Van Cutsem E. Eur J Cancer. 1999 Mar;35 Suppl 1:S1-2. doi: 10.1016/s0959-8049(99)00040-4. Eur J Cancer. 1999. PMID: 10645206 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

720 results

Search Page